BSK02 Illustration
BSK02-ODP™
BSK02-ODP™ is the first-in-class synthetic oral cancer immunotherapy generated through our dual core technology BLADE-SMART™. Unlike oral immunotherapies based on live attenuated bacteria/viruses, BSK02-ODP™ is based on ODP™, our newly designed T-cell activation platform consisting of cell-free, fully biocompatible synthetic microparticles.
BSK02-ODP – Mechanism of Action
